ClinicalTrials.gg
CompletedNCT03099304Updated Nov 17, 2022Results posted

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

A Phase 2 interventional study of Ruxolitinib cream and Vehicle cream in Vitiligo, sponsored by Incyte Corporation. Completed at 26 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
6th of 14
157 · median 90
Started
2017
the only one that year
Phase 2
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 2nd registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • depigmenting disorder
  • topical JAK inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of vitiligo.
  • Vitiligo with depigmented areas including:

    • at least 0.5% of the total body surface area (BSA) on the face (0.5% BSA is approximately equal to the area of the participant's palm [without digits]) AND
    • at least 3% of the total BSA on nonfacial areas (3% BSA is approximately equal to the area of 3 of the participant's handprints [palm plus 5 digits]).
  • Participants who agree to discontinue all agents used to treat vitiligo from screening through the final follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

Exclusion criteria

Exclusion Criteria:

  • Conditions at baseline that would interfere with evaluation of vitiligo.
  • Participants who are receiving any kind of phototherapy, including tanning beds.
  • Participants with other dermatologic disease besides vitiligo whose presence or treatments could complicate the assessment of repigmentation.
  • Participants who have used skin bleaching treatments for past treatment of vitiligo or other pigmented areas.
  • Participants who have received any of the following treatments within the minimum specified timeframes.

    • Use of any biologic, , or experimental therapy or procedure for vitiligo within 12 weeks or 5 half-lives (whichever is longer) of screening.
    • Use of laser or light-based vitiligo treatments, including tanning beds, within 8 weeks of screening.
    • Use of immunomodulating oral or systemic medications (eg, , methotrexate, cyclosporine) or topical treatments that may affect vitiligo (eg, corticosteroids, tacrolimus/pimecrolimus, retinoids) within 4 weeks of screening.
  • Use of any prior and concomitant therapy not listed above that may interfere with the objective of the study as per discretion of the investigator, including drugs that cause photosensitivity or skin pigmentation (eg, antibiotics such as tetracyclines, antifungals) within 8 weeks of screening.
  • Participants with a abnormal thyroid-stimulating hormone or free T4 at screening.
  • Participants with protocol-defined cytopenias at screening
  • Participants with severely impaired liver function.
  • Participants with impaired renal function.
  • Participants taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit.
  • Participants who have previously received JAK inhibitor therapy, systemic or topical.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Ruxolitinib cream 1.5% twice daily (BID)

    Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.

    Drug: Ruxolitinib cream

  • Experimental
    Ruxolitinib cream 1.5% once daily (QD)

    Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.

    Drug: Ruxolitinib cream · Drug: Vehicle cream

  • Experimental
    Ruxolitinib cream 0.5% QD

    Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.

    Drug: Ruxolitinib cream · Drug: Vehicle cream

  • Experimental
    Ruxolitinib cream 0.15% QD

    Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if \< 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.

    Drug: Ruxolitinib cream · Drug: Vehicle cream

  • Placebo comparator
    Vehicle BID

    Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.

    Drug: Ruxolitinib cream · Drug: Vehicle cream

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB018424 cream

  • DrugVehicle cream

    Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

    Time frame: Week 24

  2. Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52

    T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 52

  3. Dose Response on Percentage Change From Baseline in F-VASI

    Time frame: up to 156 weeks

  4. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: up to 24 weeks

  5. Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: up to 52 weeks

  6. Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: Week 24 to Week 52

  7. Number of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: up to Week 156

  8. Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: Week 52 to Week 156

  9. Mean Change From Baseline in F-VASI Score at Week 24

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 24

  10. Mean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 52, 104, and 156

  11. Percentage Change From Baseline in F-VASI Score at Week 24

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Week 24

  12. Percentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Weeks 52, 104, and 156

  13. Percentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Weeks 52, 104, and 156

  14. Percentage Change From Baseline in F-BSA Repigmentation at Week 24

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Week 24

  15. Percentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Weeks 52, 104, and 156

  16. Percentage Change From Baseline in T-BSA Repigmentation at Week 24

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Week 24

  17. Percentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

    Time frame: Baseline; Weeks 52, 104, and 156

  18. Mean Change From Baseline in T-VASI Score at Week 24

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value.

    Time frame: Baseline; Week 24

  19. Mean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.

    Time frame: Baseline; Weeks 52, 104, and 156

  20. Percentage Change From Baseline in T-VASI Score at Week 24

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  21. Percentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Weeks 52, 104, and 156

  22. Mean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Week 24

  23. Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Weeks 52 and 104

  24. Mean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Week 24

  25. Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Weeks 52 and 104

  26. Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Week 24

  27. Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Weeks 52 and 104

  28. Mean Change From Baseline in VETF Scale Scores at Week 24: Total Staging

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Week 24

  29. Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Weeks 52 and 104

  30. Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Week 24

  31. Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging

    The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

    Time frame: Baseline; Weeks 52 and 104

  32. Percentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

    Time frame: Week 24

  33. Percentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

    Time frame: Weeks 52, 104, and 156

  34. Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

    Time frame: Week 24

  35. Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

    Time frame: Weeks 52, 104, and 156

  36. Percentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24

    The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

    Time frame: Week 24

  37. Percentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156

    The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

    Time frame: Weeks 52, 104, and 156

  38. Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24

    The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

    Time frame: Week 24

  39. Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156

    The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

    Time frame: Weeks 52, 104, and 156

  40. Percentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24

    The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

    Time frame: Baseline; Week 24

  41. Percentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156

    The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

    Time frame: Baseline; Weeks 52, 104, and 156

  42. Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24

    The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

    Time frame: Baseline; Week 24

  43. Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156

    The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

    Time frame: Baseline; Weeks 52, 104, and 156

  44. Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: up to 52 weeks

  45. Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score

    A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).

    Time frame: up to 52 weeks

  46. Time to Achieve an F-PhGVA of Clear or Almost Clear

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.

    Time frame: up to 52 weeks

  47. Time to Achieve an T-PhGVA of Clear or Almost Clear

    The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.

    Time frame: up to 52 weeks

  48. Time to Achieve a PaGIC-V of Very Much Improved or Much Improved

    The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.

    Time frame: up to 52 weeks

07

Results

Posted Dec 10, 2021

Participant flow

A total of 157 participants with vitiligo were treated at 26 study centers in the United States.

DB Period: Day 1 to Week 24
Participant flow — DB Period: Day 1 to Week 24
MilestoneVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDCross-over
Started32313130330
Completed27263026300
Not completed551430
Withdrew: Adverse event110010
Withdrew: Lost to follow-up110000
Withdrew: Reason not specified000100
Withdrew: Withdrawal by subject330220
Withdrew: Protocol violation001100
DB Period: Weeks 24 to 52
Participant flow — DB Period: Weeks 24 to 52
MilestoneVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDCross-over
Started0114544470
Completed0104337450
Not completed012720
Withdrew: Protocol violation001000
Withdrew: Lost to follow-up011100
Withdrew: Adverse event000110
Withdrew: Withdrawal by subject000410
Withdrew: Reason not specified000100
104-week Open-Label Extension Period
Participant flow — 104-week Open-Label Extension Period
MilestoneVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDCross-over
Started0028212846
Completed001181223
Not completed0017131623
Withdrew: Adverse event001000
Withdrew: Lost to follow-up003216
Withdrew: Physician decision000010
Withdrew: Pregnancy000001
Withdrew: Protocol violation000001
Withdrew: Withdrawal by subject009101315
Withdrew: Other reason not specified004110

Outcome measures

PrimaryPercentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 243.132.325.850.045.5
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · exact logistic regression · p = 0.0057 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 13.79 · 95% CI 1.73 to 640.85
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · exact logistic regression · p = 0.0243 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 10.30 · 95% CI 1.24 to 487.28
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · exact logistic regression · p = <0.0001 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 28.48 · 95% CI 3.74 to 1305.2
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · exact logistic regression · p = 0.0001 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 24.66 · 95% CI 3.28 to 1121.4
SecondaryPercentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear03.29.713.39.1
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · exact logistic regression · p = 0.4936 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 1.03
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · exact logistic regression · p = 0.1140 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 4.16
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · exact logistic regression · p = 0.0501 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 6.10
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · exact logistic regression · p = 0.1257 (The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).) · Odds ratio (or): 3.89
SecondaryPercentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52

T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 525021.416.715.425.830.036.4
Statistical analysis
  • Ruxolitinib Cream 0.5% QD: 1.5% BID vs Ruxolitinib Cream 1.5% QD: 1.5 % BID · exact logistic regression · p = 0.9794 · Odds ratio (or): 1.19 · 95% CI 0.33 to 4.33The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
  • Ruxolitinib Cream 0.5% QD: 1.5% BID vs Ruxolitinib Cream 1.5% BID: 1.5% BID · exact logistic regression · p = 0.4893 · Odds ratio (or): 1.69 · 95% CI 0.51 to 5.86The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
SecondaryDose Response on Percentage Change From Baseline in F-VASI
Time frame:
up to 156 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24
ParticipantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Any TEAE2020222220
Any Grade 3 or higher TEAE00001
SecondaryNumber of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52
ParticipantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Any TEAE————262323
Any Grade 3 or higher TEAE————211
SecondaryNumber of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
Week 24 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52
ParticipantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Any TEAE9659———
Any Grade 3 or higher TEAE0000———
SecondaryNumber of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
up to Week 156
Reported as:
Count of participants · Participants
Number of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE
ParticipantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Any TEAE——————26
Any Grade 3 or higher TEAE——————1
SecondaryNumber of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
Week 52 to Week 156
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156
ParticipantsRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5% BIDRuxolitinib Cream 1.5% BID: 1.5% BIDCross-over
Any TEAE15161325
Any Grade 3 or higher TEAE0202
SecondaryMean Change From Baseline in F-VASI Score at Week 24

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · scores on a scale
Mean Change From Baseline in F-VASI Score at Week 24
scores on a scaleVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Mean Change From Baseline in F-VASI Score at Week 240.05 ± 0.11-0.39 ± 0.11-0.35 ± 0.11-0.63 ± 0.11-0.46 ± 0.10
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · Log Rank · p = 0.0056 · Least squares mean (lsm) difference: -0.44 · 95% CI -0.75 to -0.13LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · Log Rank · p = 0.0095 · Lsm difference: -0.40 · 95% CI -0.70 to -0.10LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · Log Rank · p = <0.0001 · Lsm difference: -0.68 · 95% CI -0.99 to -0.37LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · Log Rank · p = 0.0011 · Lsm difference: -0.51 · 95% CI -0.80 to -0.21LSM difference = treatment minus vehicle
SecondaryMean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · scores on a scale
Mean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156
scores on a scaleRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Baseline0.77 ± 0.3871.21 ± 0.8911.66 ± 0.9931.14 ± 0.7141.22 ± 0.7051.45 ± 0.9801.26 ± 0.808
Change from Baseline at Week 52-0.59 ± 0.459-0.67 ± 0.811-1.02 ± 1.058-0.58 ± 0.783-0.58 ± 0.578-0.74 ± 0.797-0.76 ± 0.610
Change from Baseline at Week 104-0.66 ± 0.444-0.97 ± 1.061-1.79 ± 1.077-0.87 ± 0.903-1.00 ± 0.697-1.17 ± 0.961-0.99 ± 0.817
Change from Baseline at Week 156-0.66 ± 0.124-0.98 ± 1.092-1.40 ± 1.018-0.65 ± 0.557-0.71 ± 0.490-0.95 ± 0.949-1.23 ± 0.887
SecondaryPercentage Change From Baseline in F-VASI Score at Week 24

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in F-VASI Score at Week 24
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-VASI Score at Week 246.02 ± 7.23-30.69 ± 7.39-29.10 ± 6.93-40.00 ± 7.39-37.78 ± 6.89
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · Log Rank · p = 0.0005 · Lsm difference: -36.71 · 95% CI -57.15 to -16.27LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · Log Rank · p = 0.0006 · Lm difference: -35.12 · 95% CI -54.91 to -15.33LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · Log Rank · p = <0.0001 · Lsm difference: -46.02 · 95% CI -66.47 to -25.57LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · Log Rank · p = <0.0001 · Lsm difference: -43.80 · 95% CI -63.52 to -24.07LSM difference = treatment minus vehicle
SecondaryPercentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · percent change
Percentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-72.21 ± 26.837-50.60 ± 34.954-52.43 ± 36.412-40.79 ± 37.082-45.54 ± 35.148-55.63 ± 42.823-57.34 ± 50.115
Week 104-77.67 ± 22.974-71.12 ± 31.087-82.87 ± 32.756-60.28 ± 64.708-74.89 ± 25.524-77.76 ± 24.086-78.78 ± 28.400
Week 156-87.95 ± 8.207-66.83 ± 45.106-91.25 ± 14.631-59.16 ± 42.627-76.25 ± 20.126-76.76 ± 23.924-89.52 ± 14.899
SecondaryPercentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 5290.064.350.038.545.243.357.6
Week 10488.987.588.977.878.983.389.5
Week 156100.075.0100.060.087.587.5100.0
SecondaryPercentage Change From Baseline in F-BSA Repigmentation at Week 24

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in F-BSA Repigmentation at Week 24
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-BSA Repigmentation at Week 246.49 ± 32.028-19.82 ± 24.928-17.55 ± 25.453-19.53 ± 38.612-27.76 ± 30.996
SecondaryPercentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · percent change
Percentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-55.18 ± 36.091-37.94 ± 32.569-33.39 ± 40.095-15.64 ± 29.733-34.67 ± 37.769-38.37 ± 38.660-44.29 ± 35.253
Week 104-42.86 ± 31.282-67.61 ± 29.683-76.57 ± 31.260-45.65 ± 59.599-54.49 ± 34.411-63.56 ± 28.543-59.49 ± 38.186
Week 156-33.04 ± 6.313-59.17 ± 40.586-90.50 ± 16.240-16.89 ± 56.706-55.80 ± 33.310-59.58 ± 27.106-72.58 ± 31.024
SecondaryPercentage Change From Baseline in T-BSA Repigmentation at Week 24

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in T-BSA Repigmentation at Week 24
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-BSA Repigmentation at Week 243.35 ± 8.314-13.97 ± 25.396-10.83 ± 15.646-17.19 ± 22.490-13.60 ± 20.443
SecondaryPercentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · percent change
Percentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-39.53 ± 32.599-8.72 ± 26.010-2.72 ± 23.014-8.73 ± 21.630-15.13 ± 21.296-27.33 ± 27.568-27.59 ± 26.770
Week 104-42.42 ± 32.208-30.49 ± 36.289-30.08 ± 30.717-21.08 ± 30.323-33.19 ± 30.127-33.94 ± 26.573-32.46 ± 33.190
Week 156-59.44 ± 51.920-46.58 ± 30.723-34.93 ± 35.391-37.95 ± 23.651-29.59 ± 32.261-10.55 ± 53.863-46.88 ± 19.304
SecondaryMean Change From Baseline in T-VASI Score at Week 24

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · scores on a scale
Mean Change From Baseline in T-VASI Score at Week 24
scores on a scaleVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Mean Change From Baseline in T-VASI Score at Week 240.57 ± 0.92-2.27 ± 0.94-2.18 ± 0.88-4.51 ± 0.94-3.52 ± 0.87
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · Log Rank · p = 0.0326 · Lsm difference: -2.84 · 95% CI -5.44 to -0.24LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · Log Rank · p = 0.0333 · Lsm difference: -2.74 · 95% CI -5.26 to -0.22LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · Log Rank · p = 0.0002 · Lsm difference: -5.08 · 95% CI -7.68 to -2.48LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · Log Rank · p = 0.0016 · Lsm difference: -4.08 · 95% CI -6.59 to -1.57LSM difference = treatment minus vehicle
SecondaryMean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · scores on a scale
Mean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156
scores on a scaleRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Baseline9.56 ± 7.09013.47 ± 11.65522.82 ± 19.18720.75 ± 15.97318.43 ± 15.36320.55 ± 18.48816.94 ± 14.256
Change from Baseline at Week 52-4.59 ± 4.979-2.88 ± 2.934-3.21 ± 4.536-3.88 ± 5.642-3.97 ± 6.284-7.37 ± 7.403-6.14 ± 7.442
Change from Baseline at Week 104-6.02 ± 5.476-5.32 ± 5.615-9.71 ± 9.398-6.62 ± 7.054-7.19 ± 9.079-10.77 ± 9.658-7.74 ± 5.927
Change from Baseline at Week 156-2.33 ± 0.269-10.23 ± 13.533-11.31 ± 12.185-7.82 ± 4.209-4.72 ± 3.622-7.02 ± 9.577-8.77 ± 4.996
SecondaryPercentage Change From Baseline in T-VASI Score at Week 24

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in T-VASI Score at Week 24
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-VASI Score at Week 242.65 ± 4.89-20.88 ± 5.00-15.82 ± 4.69-27.16 ± 4.99-22.91 ± 4.65
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · Log Rank · p = 0.0010 · Lsm difference: -23.53 · 95% CI -37.35 to -9.71LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · Log Rank · p = 0.0072 · Lsm difference: -18.47 · 95% CI -31.86 to -5.08LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · Log Rank · p = <0.0001 · Lsm difference: -29.81 · 95% CI -43.61 to -16.00LSM difference = treatment minus vehicle
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · Log Rank · p = 0.0002 · Lsm difference: -25.56 · 95% CI -38.89 to -12.22LSM difference = treatment minus vehicle
SecondaryPercentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Mean · percent change
Percentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-50.71 ± 33.310-25.12 ± 31.556-19.75 ± 26.484-20.00 ± 29.264-24.67 ± 29.649-41.90 ± 35.865-41.67 ± 26.451
Week 104-60.96 ± 32.259-49.35 ± 39.319-49.07 ± 29.091-38.70 ± 38.663-46.44 ± 31.668-52.14 ± 33.559-50.03 ± 26.905
Week 156-71.10 ± 31.448-59.33 ± 40.055-47.31 ± 34.610-49.96 ± 27.555-44.69 ± 30.718-14.97 ± 58.982-62.80 ± 20.904
SecondaryMean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Week 24
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading
scores on a scaleVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Baseline1.78 ± 2.1662.74 ± 2.4221.84 ± 2.2381.83 ± 2.1021.21 ± 2.233
Change from Baseline at Week 24-1.12 ± 2.566-3.15 ± 3.246-3.27 ± 3.532-3.12 ± 2.971-3.58 ± 3.042
SecondaryMean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Weeks 52 and 104
Reported as:
Mean · scores on a scale
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading
scores on a scaleRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Baseline2.73 ± 2.3282.43 ± 2.2771.21 ± 2.6072.21 ± 1.9681.84 ± 2.2381.83 ± 2.1021.21 ± 2.233
Change from Baseline at Week 52-4.70 ± 3.683-4.14 ± 3.592-3.83 ± 3.538-3.85 ± 3.211-3.48 ± 3.622-3.86 ± 3.395-3.66 ± 2.742
Change from Baseline at Week 104-5.00 ± 4.153-4.25 ± 3.196-4.22 ± 3.667-5.11 ± 3.371-3.16 ± 3.516-3.56 ± 3.034-3.26 ± 3.034
SecondaryMean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Week 24
Reported as:
Mean · scores on a scale
Mean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area
scores on a scaleVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Baseline22.81 ± 20.84316.26 ± 11.00622.35 ± 20.87824.63 ± 22.23620.79 ± 16.192
Change from Baseline at Week 240.38 ± 1.329-1.08 ± 3.867-2.43 ± 4.797-3.27 ± 6.744-2.71 ± 4.591
SecondaryMean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Weeks 52 and 104
Reported as:
Mean · scores on a scale
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area
scores on a scaleRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Baseline9.18 ± 6.50916.43 ± 11.97924.50 ± 21.84124.50 ± 18.79822.35 ± 20.87824.63 ± 22.23620.79 ± 16.192
Change from Baseline at Week 52-3.10 ± 3.814-1.86 ± 2.905-1.17 ± 3.486-1.92 ± 6.211-3.93 ± 7.191-5.71 ± 8.463-4.48 ± 6.127
Change from Baseline at Week 104-3.89 ± 4.226-4.75 ± 5.994-5.11 ± 4.226-4.44 ± 7.367-8.00 ± 10.392-7.78 ± 8.695-6.26 ± 6.682
SecondaryPercentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area2.61 ± 9.497-10.61 ± 29.408-13.87 ± 25.296-14.09 ± 20.321-13.10 ± 17.605
SecondaryPercentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Weeks 52 and 104
Reported as:
Mean · percent change
Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-32.01 ± 35.629-7.39 ± 21.571-10.57 ± 22.300-7.13 ± 25.967-19.73 ± 30.730-22.36 ± 23.593-25.41 ± 24.049
Week 104-39.30 ± 37.071-23.05 ± 29.233-34.03 ± 27.992-18.49 ± 36.527-35.55 ± 34.039-30.40 ± 22.940-29.19 ± 39.767
SecondaryMean Change From Baseline in VETF Scale Scores at Week 24: Total Staging

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Week 24
Reported as:
Mean · scores on a scale
Mean Change From Baseline in VETF Scale Scores at Week 24: Total Staging
scores on a scaleVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Baseline10.03 ± 3.5159.29 ± 3.01310.03 ± 3.9459.97 ± 3.0008.42 ± 3.464
Change from Baseline at Week 24-1.15 ± 3.184-1.62 ± 2.282-1.57 ± 2.687-1.96 ± 3.561-0.74 ± 2.633
SecondaryMean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Weeks 52 and 104
Reported as:
Mean · scores on a scale
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging
scores on a scaleRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Baseline8.64 ± 2.9088.43 ± 2.90111.29 ± 2.12810.07 ± 3.66810.03 ± 3.9459.97 ± 3.0008.42 ± 3.464
Change from Baseline at Week 52-3.10 ± 3.247-1.29 ± 2.301-2.17 ± 3.157-2.62 ± 2.844-2.41 ± 3.030-3.48 ± 2.960-1.38 ± 2.555
Change from Baseline at Week 104-3.44 ± 3.358-2.75 ± 3.694-2.22 ± 3.866-2.89 ± 1.537-2.84 ± 2.754-4.00 ± 3.049-1.68 ± 2.730
SecondaryPercentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging
percent changeVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging-7.58 ± 18.740-17.52 ± 22.267-13.55 ± 21.200-17.00 ± 31.798-4.46 ± 38.916
SecondaryPercentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging

The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).

Time frame:
Baseline; Weeks 52 and 104
Reported as:
Mean · percent change
Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging
percent changeRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52-33.48 ± 25.022-12.70 ± 24.012-17.31 ± 22.623-23.88 ± 19.262-21.45 ± 24.571-30.00 ± 22.563-12.99 ± 29.585
Week 104-37.20 ± 29.132-24.29 ± 30.439-16.55 ± 27.268-32.06 ± 12.311-27.76 ± 23.202-35.20 ± 23.904-14.09 ± 26.969
SecondaryPercentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
00.00.00.00.00.0
10.03.29.713.39.1
26.316.116.120.027.3
340.664.561.336.754.5
434.40.09.716.73.0
Missing at the visit18.816.13.213.36.1
Statistical analysis
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.15% QD · exact logistic regression · p = 0.4936 · Odds ratio (or): 1.03The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 0.5% QD · exact logistic regression · p = 0.1140 · Odds ratio (or): 4.16The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% QD · exact logistic regression · p = 0.0501 · Odds ratio (or): 6.10The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
  • Vehicle Twice Daily (BID) vs Ruxolitinib Cream 1.5% BID · exact logistic regression · p = 0.1257 · Odds ratio (or): 3.89The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \>30).
SecondaryPercentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

Time frame:
Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52, 00.00.00.00.06.94.80.0
Week 52, 120.014.38.37.710.314.324.1
Week 52, 260.07.133.346.217.228.637.9
Week 52, 320.071.450.046.255.242.931.0
Week 52, 40.07.18.30.010.39.56.9
Week 104, 00.00.011.111.15.311.115.8
Week 104, 155.650.033.322.231.633.331.6
Week 104, 233.325.033.322.236.827.826.3
Week 104, 311.125.011.144.426.327.821.1
Week 104, 40.00.011.10.00.00.05.3
Week 156, 00.00.060.00.025.00.033.3
Week 156, 10.050.00.060.012.537.555.6
Week 156, 2100.00.020.020.050.025.00.0
Week 156, 30.050.020.020.012.537.511.1
Week 156, 40.00.00.00.00.00.00.0
SecondaryPercentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
00.00.00.00.00.0
10.00.03.30.03.2
211.523.120.023.135.5
357.776.970.061.558.1
430.80.06.715.43.2
SecondaryPercentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.

Time frame:
Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52, 00.00.00.00.00.00.00.0
Week 52, 110.00.00.00.010.30.06.9
Week 52, 250.035.78.37.713.828.655.2
Week 52, 340.057.183.384.669.061.931.0
Week 52, 40.07.18.37.76.99.56.9
Week 104, 00.00.00.00.00.00.00.0
Week 104, 10.025.011.111.15.30.00.0
Week 104, 277.837.533.333.368.455.663.2
Week 104, 322.237.544.455.626.327.836.8
Week 104, 40.00.011.10.00.016.70.0
Week 156, 00.00.00.00.00.00.00.0
Week 156, 150.050.020.00.025.00.011.1
Week 156, 250.00.00.060.050.062.566.7
Week 156, 30.050.060.040.025.025.022.2
Week 156, 40.00.020.00.00.012.50.0
SecondaryPercentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24

The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
00.00.00.00.00.0
19.416.112.916.733.3
231.338.741.940.027.3
328.125.835.520.024.2
415.63.26.510.09.1
Missing at the visit15.616.13.213.36.1
SecondaryPercentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156

The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

Time frame:
Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52, 00.00.00.00.00.00.03.4
Week 52, 150.021.416.730.824.130.044.8
Week 52, 240.028.683.346.237.930.024.1
Week 52, 310.050.00.023.134.530.020.7
Week 52, 40.00.00.00.03.410.06.9
Week 104, 00.00.00.00.05.35.65.3
Week 104, 166.750.022.255.642.144.436.8
Week 104, 222.237.555.633.336.816.747.4
Week 104, 311.112.522.011.115.822.25.3
Week 104, 40.00.00.00.00.011.15.3
Week 156, 00.00.020.00.012.50.011.1
Week 156, 150.050.00.080.037.537.544.4
Week 156, 250.050.080.020.050.050.022.2
Week 156, 30.00.00.00.00.00.011.1
Week 156, 40.00.00.00.00.012.511.1
SecondaryPercentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24

The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
00.00.03.20.00.0
16.312.99.716.715.2
237.535.538.733.345.5
331.329.035.530.021.2
49.46.59.76.712.1
Missing at the visit15.616.13.213.36.1
SecondaryPercentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156

The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.

Time frame:
Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52, 00.00.00.00.00.00.00.0
Week 52, 120.07.18.30.013.825.013.8
Week 52, 260.050.041.769.248.340.062.1
Week 52, 320.042.950.023.127.625.010.3
Week 52, 40.00.00.07.710.310.013.8
Week 104, 00.00.00.00.00.00.00.0
Week 104, 133.325.00.00.036.822.215.8
Week 104, 255.650.044.477.842.144.457.9
Week 104, 311.125.055.622.215.816.721.1
Week 104, 40.00.00.00.05.316.75.3
Week 156, 00.00.00.00.00.00.00.0
Week 156, 150.025.020.020.037.512.533.3
Week 156, 250.075.040.040.050.037.555.6
Week 156, 30.00.040.040.012.525.00.0
Week 156, 40.00.00.00.00.025.011.1
SecondaryPercentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24

The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
17.43.86.711.56.5
20.019.213.319.222.6
322.234.650.053.835.5
437.026.923.311.525.8
522.211.56.70.09.7
611.13.80.03.80.0
70.00.00.00.00.0
SecondaryPercentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156

The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 52, 10.07.18.37.710.34.813.8
Week 52, 230.014.325.023.120.747.631.0
Week 52, 330.042.958.346.255.238.127.6
Week 52, 420.07.18.315.46.99.520.7
Week 52, 520.028.60.07.73.40.06.9
Week 52, 60.00.00.00.03.40.00.0
Week 52, 70.00.00.00.00.00.00.0
Week 104, 111.125.011.122.210.522.221.1
Week 104, 233.312.544.433.336.838.936.8
Week 104, 322.262.533.322.247.422.236.8
Week 104, 422.20.011.122.25.311.10.0
Week 104, 511.10.00.00.00.00.05.3
Week 104, 60.00.00.00.00.05.60.0
Week 104, 70.00.00.00.00.00.00.0
Week 156, 150.025.020.020.012.512.511.1
Week 156, 250.025.020.060.025.050.077.8
Week 156, 30.050.040.00.062.512.511.1
Week 156, 40.00.020.020.00.00.00.0
Week 156, 50.00.00.00.00.012.50.0
Week 156, 60.00.00.00.00.012.50.0
Week 156, 70.00.00.00.00.00.00.0
SecondaryPercentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24

The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24
percentage of participantsVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 247.423.120.030.829.0
SecondaryPercentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156

The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.

Time frame:
Baseline; Weeks 52, 104, and 156
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156
percentage of participantsRuxolitinib Cream 0.15% QDVehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BIDVehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BIDRuxolitinib Cream 0.5% QD: 1.5% BIDRuxolitinib Cream 1.5% QD: 1.5 % BIDRuxolitinib Cream 1.5% BID: 1.5% BID
Week 5230.021.433.330.831.052.444.8
Week 10444.437.555.655.647.461.157.9
Week 156100.050.040.080.037.562.588.9
SecondaryTime to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
up to 52 weeks
Reported as:
Median · days
Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score
daysVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 ScoreNA (NA to NA)197.0 (127.0 to NA)339.0 (195.0 to NA)172.0 (127.0 to 323.0)170.0 (127.0 to NA)
SecondaryTime to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score

A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).

Time frame:
up to 52 weeks
Reported as:
Median · days
Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score
daysVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 ScoreNA (NA to NA)NA (204.0 to NA)NA (366.0 to NA)NA (192.0 to NA)376.0 (276.0 to NA)
SecondaryTime to Achieve an F-PhGVA of Clear or Almost Clear

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.

Time frame:
up to 52 weeks
Reported as:
Median · days
Time to Achieve an F-PhGVA of Clear or Almost Clear
daysVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Time to Achieve an F-PhGVA of Clear or Almost ClearNA (NA to NA)372.0 (274.0 to NA)NA (369.0 to NA)NA (NA to NA)NA (367.0 to NA)
SecondaryTime to Achieve an T-PhGVA of Clear or Almost Clear

The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.

Time frame:
up to 52 weeks
Reported as:
Median · days
Time to Achieve an T-PhGVA of Clear or Almost Clear
daysVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Time to Achieve an T-PhGVA of Clear or Almost ClearNA (NA to NA)372.0 (274.0 to NA)NA (NA to NA)NA (NA to NA)NA (369.0 to NA)
SecondaryTime to Achieve a PaGIC-V of Very Much Improved or Much Improved

The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.

Time frame:
up to 52 weeks
Reported as:
Median · days
Time to Achieve a PaGIC-V of Very Much Improved or Much Improved
daysVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Time to Achieve a PaGIC-V of Very Much Improved or Much ImprovedNA (NA to NA)NA (274.0 to NA)NA (290.0 to NA)282.0 (169.0 to NA)281.0 (178.0 to NA)

Adverse events

Collected over Up to 180 weeks (156-week treatment period plus 6-month follow-up period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Twice Daily (BID)0/32 (0%)0/32 (0%)14/32 (43.8%)
Ruxolitinib Cream 0.15% Once Daily (QD)0/31 (0%)0/31 (0%)19/31 (61.3%)
Ruxolitinib Cream 0.5% QD0/45 (0%)2/45 (4.4%)23/45 (51.1%)
Ruxolitinib Cream 1.5% QD0/44 (0%)1/44 (2.3%)20/44 (45.5%)
Ruxolitinib Cream 1.5% BID0/130 (0%)4/130 (3.1%)45/130 (34.6%)
Most frequent serious events
Most frequent serious events
EventVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% Once Daily (QD)Ruxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
SeizureNervous system disorders0/320/310/451/440/130
Coronary artery occlusionCardiac disorders0/320/311/450/440/130
Oesophageal achalasiaGastrointestinal disorders0/320/311/450/440/130
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/310/450/441/130
Cholecystitis acuteHepatobiliary disorders0/320/310/450/441/130
OsteoarthritisMusculoskeletal and connective tissue disorders0/320/310/450/441/130
Subdural haematomaInjury, poisoning and procedural complications0/320/310/450/441/130
Most frequent other events
Showing 10 of 21
Most frequent other events
EventVehicle Twice Daily (BID)Ruxolitinib Cream 0.15% Once Daily (QD)Ruxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BID
Application site pruritusGeneral disorders3/326/313/453/442/130
BronchitisInfections and infestations0/325/310/451/446/130
AcneSkin and subcutaneous tissue disorders1/324/315/454/4412/130
NasopharyngitisInfections and infestations4/324/315/455/446/130
PruritusSkin and subcutaneous tissue disorders3/321/315/455/446/130
Upper respiratory tract infectionInfections and infestations0/321/315/451/448/130
Skin exfoliationSkin and subcutaneous tissue disorders1/323/311/451/441/130
Dermatitis contactSkin and subcutaneous tissue disorders3/320/311/452/441/130
HeadacheNervous system disorders3/321/310/453/442/130
SinusitisInfections and infestations1/322/311/452/449/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Mean46.3 ± 13.1145.1 ± 11.4653.8 ± 14.3446.7 ± 11.7349.5 ± 12.2848.3 ± 12.85
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Female201812191584
Male121319111873
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Hispanic or Latino10666533
Not Hispanic or Latino2122232127114
Not Reported121307
Unknown000011
Captured as "Other"011002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
White/Caucasian2629252329132
Black/African-American5042314
Asian101215
Mexican010001
Nigerian/West African010001
Cuban001001
Spanish000101
Hispanic000101
Caucasian, Black, and Asian000101
Facial Body Surface Area (F-BSA) Involvement
Facial Body Surface Area (F-BSA) Involvement(percentage of facial surface area)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Mean1.44 ± 0.8381.35 ± 0.8581.40 ± 0.7601.67 ± 0.9531.55 ± 0.8921.48 ± 0.858
Total Body Surface Area (T-BSA) Involvement
Total Body Surface Area (T-BSA) Involvement(percentage of total body surface area)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Mean23.54 ± 20.96017.56 ± 10.92522.96 ± 21.44924.81 ± 20.05621.46 ± 16.82022.05 ± 18.377
Face Vitiligo Area Scoring Index (F-VASI)
Face Vitiligo Area Scoring Index (F-VASI)(scores on a scale)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Mean1.21 ± 0.8451.19 ± 0.7541.22 ± 0.7051.45 ± 0.9801.26 ± 0.8071.26 ± 0.817
Total Body Vitiligo Area Scoring Index (T-VASI)
Total Body Vitiligo Area Scoring Index (T-VASI)(scores on a scale)Vehicle Twice Daily (BID)Ruxolitinib Cream 0.15% QDRuxolitinib Cream 0.5% QDRuxolitinib Cream 1.5% QDRuxolitinib Cream 1.5% BIDTotal
Mean19.40 ± 18.51214.57 ± 9.04918.43 ± 15.36320.55 ± 18.48816.94 ± 14.25617.96 ± 15.451
08

Study locations

26 sites
  • UNIVERSITY OF ALABAMA AT BIRMINGHAM (UAB), 1802 6th Ave S
    Birmingham, Alabama 35233, United States
  • BURKE PHARMACEUTICAL RESEARCH LLC, 3633 Central Ave
    Hot Springs, Arkansas 71913, United States
  • NORTHWEST AR CLINICAL TRIALS CENTER, PLLC/HULL DERMATOLOGY, PA, 500 S 52nd Street
    Rogers, Arkansas 72758, United States
  • THE VITILIGO & PIGMENTATION INSTITUE OF SOUTHERN CALIFORNIA, 5670 Wilshire Boulevard
    Los Angeles, California 90036, United States
  • DERMATOLOGY RESEARCH ASSOCIATES- LOS ANGELES, 8930 S Sepulveda Blvd
    Los Angeles, California 90045, United States
  • DERMATOLOGY SPECIALISTS, 3629 Vista Way
    Oceanside, California 92056, United States
  • CLINICAL RESEARCH CENTER OF CT, 27 Hospital Avenue
    Danbury, Connecticut 06810, United States
  • LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC/ AMERIDERM RESEARCH, 725 W Granada Blvd
    Ormond Beach, Florida 32174, United States
  • EMORY UNIVERSITY, 1525 Clifton Road
    Atlanta, Georgia 30322, United States
  • NORTHWESTERN UNIVERSITY, 676 N Saint Clair
    Chicago, Illinois 60611, United States
  • DAWES FRETZIN CLINICAL RESEARCH GROUP, 8103 Clearvista Parkway
    Indianapolis, Indiana 46256, United States
  • DS RESEARCH, 2241 Green Valley Road
    New Albany, Indiana 47150, United States
  • TULANE UNIVERSITY, 1415 Tulane Avenue
    New Orleans, Louisiana 70112, United States
  • Tufts Medical Center, 260 Tremont Street
    Boston, Massachusetts 02111, United States
  • UNIVERSITY OF MASSACHUESETTS, 364 Plantation Street
    Worcester, Massachusetts 01605, United States
  • HAMZAVI DERMATOLOGY, 3031 W Grand Blvd
    Detroit, Michigan 48059, United States
  • WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY, 969 N. Mason Road
    Saint Louis, Missouri 63141, United States
  • ACTIVMED PRACTICES & RESEARCH, INC, 110 Corporate Drive
    Portsmouth, New Hampshire 03801, United States
  • ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI MEDICAL CENTER- DERMATOLOGY ASSOCIATES, 5 E 98th Street
    New York, New York 11209, United States
  • WAKE FOREST UNIVERSITY HEALTH SCIENCES, Medical Center Boulevard
    Winston-Salem, North Carolina 27157, United States
  • CENTRAL SOONER RESEARCH, 900 N Porter Ave
    Norman, Oklahoma 73071, United States
  • RHODE ISLAND HOSPITAL, 593 Eddy Street
    Providence, Rhode Island 02903, United States
  • ARLINGTON RESEARCH CENTER, INC., 711 East Lamar Boulevard
    Arlington, Texas 76011, United States
  • MENTER DERMATOLOGY RESEARCH INSTITUTE, 3900 Junius Street
    Dallas, Texas 75246, United States
  • UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DEPARTMENT OF DERMATOLOGY, 5323 Harry Hines Blvd
    Dallas, Texas 75390, United States
  • THE DERMATOLOGY AND LASER CENTER OF SAN ANTONIO, 7810 Louis Pasteur
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 Jul 11;396(10244):110-120. doi: 10.1016/S0140-6736(20)30609-7. PubMed 32653055 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Sep 2018, 15 months.

Results were first posted in Dec 2021, 3 years 2 months after primary completion. A results delay was requested in Sep 2019.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Apr 4, 2017
StartActual
Jun 7, 2017
Primary completionActual
Sep 12, 2018
CompletionActual
Sep 8, 2021
Results delay requested
Sep 10, 2019
Results first posted
Dec 10, 2021
Last update
Nov 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03099304
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Jun 7, 2017
Primary completion
Sep 12, 2018
Completion
Sep 8, 2021
Results posted
Dec 10, 2021
Last update
Nov 17, 2022

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion